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Blood sampling catheters or 
oxygen electrodes were inserted 
into the aorta or vena cava of 
penguins under anaethesia. After 
recovery, the birds were allowed 
to dive through the isolated dive 
hole, which ensured that the 
birds returned to this hole. After 
one or two days of diving, the 
equipment was removed, data 
recorded and the birds allowed 
to recover.
On analysis of the data from 
these dives, the researchers found 
that the penguins were capable of 
reaching extremely low levels of 
blood oxygen at the time of their 
return to the surface of the dive 
hole. The lowest of the air sac 
values was significant in relation 
to the results from other birds. The 
lowest values in emperor penguins 
are less than that in air breathed in 
by birds flying at altitudes of more 
than ,500 metres and lower than 
that found in birds flying at these 
high altitudes, such as the bar-
headed goose.
The researchers found that 
the remarkably low levels of 
intervascular and air sac levels 
of oxygen in emperor penguins 
is achieved at least in part from 
the optimum management of 
oxygen reserves and extreme 
hypoxemic tolerance. In particular, 
the birds’ haemoglobin with high 
oxygen affinity enhanced blood 
oxygen content during hypoxemia 
and allowed the depletion of 
respiratory reserves.
The oxygen levels were 
also extremely low by human 
comparison, even with patients 
undergoing treatment for 
hypoxemia and from climbers at 
the top of Mount Everest. 
As well as revealing a highly 
specialised mechanism by which 
emperor penguins can catch 
their food, the authors believe the 
novel physiological properties 
may also help to develop models 
for improved understanding and 
treatment of human hypoxemic 
and ischemic pathologies.
Extreme: An emperor penguin begins a dive in which oxygen levels may reach extraor-
dinarily low levels. (Photo: K. Ponganis.)Q & A
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He did undergraduate work 
with Boris Magasanik at MIT 
(SB, SM 1974), graduate work 
with Ron Davis at Stanford (PhD 
1979), and a brief postdoctoral 
stint at the MRC Laboratory of 
Molecular Biology in Cambridge, 
UK with Sydney Brenner. During 
his graduate work, he was the 
first to functionally express a 
eukaryotic protein gene (yeast 
his3) in Escherichia coli and to 
use a reverse genetic approach 
to identify and map eukaryotic 
promoter elements in cellular 
genes. This work directly led into 
a career that has spanned many 
areas of transcriptional regulation, 
specifically the intricate interplay 
of activators, repressors, and 
co-regulatory complexes with 
the basic RNA polymerase 
II machinery, and the role of 
chromatin structure in gene 
expression. More recently, he has 
incorporated functional genomic 
approaches to complement more 
classical analyses of individual 
genes and proteins. Despite 
a degree in biochemistry and 
affiliation with a biochemistry 
department, he is a molecular 
biologist and geneticist interested 
in mechanisms that occur in living 
cells.
How did you become interested 
in biology? For most of my 
childhood, my academic interest 
was mathematics, and I didn’t 
care much about plants and 
animals — unlike my brother 
Gary who was very interested 
in butterflies, dolphins and 
other creatures, and is now 
a developmental biologist at 
Columbia University. I visited 
the electron microscope at 
Rockefeller University and saw 
images of eukaryotic cells, 
courtesy of Jim Hirsch, who was 
a professor of cell biology there 
and lived across the street. My 
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the age of 2, when I read books 
on heredity, human genetics, 
DNA and the genetic code (which 
was rather incomplete at the 
time). I have no memory of the 
specific books or how I came 
to read them. I do remember 
Vance Packard’s book Animal 
IQ: The Human Side of Animals, 
and giving a ‘seminar’ on this to 
my class, complete with home-
made visual aids. I was asked 
to give the same talk to every 
class in the school, and this 
started my life- long pleasure in 
giving scientific talks. The initial 
sparks from these books didn’t 
immediately translate into a 
career plan, but they undoubtedly 
contributed to the excitement I 
felt upon discovering molecular 
biology as an undergraduate 
at MIT. And, learning about the 
pioneering work of Jacob and 
Monod initiated my life-long 
fascination with the field of gene 
regulation.
Who were important influences 
in your career? From Boris 
Magasanik, who combined 
classical microbiology with 
genetics and biochemistry, 
I learned the value of a 
multidisciplinary approach. Ethan 
Signer’s famed seminar course 
at MIT on critical evaluation 
and logical analysis of scientific 
papers was instrumental in 
teaching me how scientific 
progress really proceeds, and 
it has served as a model for 
graduate courses in many 
institutions. From Ron Davis, I 
developed a life-long appreciation 
about the experimental details 
and physical principles that 
underlie laboratory experiments, 
and the development of new 
methods to solve biological 
problems. Lastly, I was lucky to 
have pursued my graduate and 
postdoctoral work in the Stanford 
Biochemistry department and 
the MRC Laboratory of Molecular 
Biology. Both were relatively small 
with exceptional faculty, postdocs 
and students who were highly 
interactive in an atmosphere 
that was collegial, informal and 
non-hierarchical, yet scientifically 
demanding. I particularly liked the 
fact that my labmates came from different research groups (very 
rare today, and a missed source 
of learning) and that funding 
issues never came up.
How did you start working on 
eukaryotic gene regulation? 
Inspired by Jacques Monod’s 
famous comment “anything that 
is true of E. coli must be true of 
elephants, except more so”, I 
wanted to extend the Jacob and 
Monod paradigm to eukaryotic 
organisms. I didn’t have a clear 
idea about how to do this until my 
day-long interview for becoming 
a graduate student at Stanford, 
when I first heard about the 
pioneering work on recombinant 
DNA technology. I decided on the 
spot that this was how I would 
study eukaryotic gene regulation 
for my PhD.
When I got to Stanford  
 months later, I wanted to clone 
a eukaryotic protein-coding 
gene and decided to do this 
by functional complementation 
in E. coli. This was viewed as 
a speculative long-shot given 
the standard assumption that 
the functional barrier between 
eukaryotes and prokaryotes  
was very high. However, I  
reasoned that the common 
genetic code and the ability 
of E. coli to initiate translation 
at internal AUG codons would 
permit synthesis of the correct 
eukaryotic protein (introns had 
yet to be discovered!), provided 
there was any reasonable level 
of transcription throughout 
the region. This worked, and I 
cloned the yeast his3 gene and 
subsequently showed that  
E. coli was producing the encoded 
yeast enzyme. I then used a 
combination of recombinant DNA 
manipulations and genetic tricks 
of bacteriophage λ to generate 
a set of deletion mutants. What 
was then needed was the ability 
to transform DNA into yeast, a 
problem solved by Gerry Fink. 
I immediately developed the 
initial yeast vectors, introduced 
the deletion mutants back into 
yeast cells, and analyzed the 
phenotypic consequences, 
thereby generating the first 
functional analysis of a promoter 
region of a eukaryotic cellular 
gene. Much of my subsequent work for nearly three decades 
derives from these initial 
experiments.
What was it like during the 
early days of recombinant DNA 
technology? Like the beginning 
of any revolution, it was very 
exciting and constantly changing. 
Many people recognized that 
a new era of biology was on 
the horizon, but even so, I 
think we underestimated the 
future impact. Ground-breaking 
techniques — molecular cloning, 
enzymatic manipulations of DNA 
and reverse genetic analysis, 
Southern, northern, and western 
blotting, DNA sequencing, 
monoclonal antibodies — were 
developed when I was a graduate 
student, and I was lucky to be 
part of the small recombinant 
DNA community that used them 
with home-made materials and 
anecdotal knowledge. Shortly 
thereafter, biological supply 
companies quickly sprouted, and 
they disseminated the necessary 
materials and expertise to the 
broad community of biologists. 
It is hard now to imagine 
biological research without these 
techniques.
What fundamental principles 
of transcriptional regulation 
are specific to eukaryotes? 
Many fundamental principles are 
universal, and were established 
from classical studies in 
prokaryotes that unfortunately 
are often now forgotten. But, 
eukaryotes clearly use new 
principles and unexpected 
mechanisms, among which are 
the following: ) Combinatorial 
regulation that makes possible 
the overwhelming complexity of 
gene expression patterns. This 
occurs primarily via synergistic 
activation by multiple proteins 
bound at enhancers, but also 
through interactions within 
and between multiprotein 
families of transcription 
factors. 2) Structurally and 
functionally autonomous 
modules in transcription 
factors for regulatory diversity 
and evolutionary flexibility. 
3) Regulation of transcription 
factors by shuttling between the 
nucleus and cytoplasm. 4) Tight 
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post-transcription processes 
such as mRNA capping, 
splicing, polyadenylation and 
nuclear export. 5) Co-regulatory 
complexes that transmit 
information from proteins bound 
at specific genome locations to 
the core transcription machinery. 
) The chromatin template which 
acts as a regulated scaffold for 
transcription factors. 
How important is chromatin 
structure for transcription? The 
role of chromatin in transcription 
has had a schizophrenic history. 
Before 975, the transcription 
field largely ignored chromatin, 
even though a correlation 
between histone acetylation and 
transcriptional activity had been 
noted in the early 90s. With the 
discovery of nucleosomes and 
the use of nuclease sensitivity 
assays, chromatin became trendy 
and was frequently invoked to 
explain unknown aspects of gene 
regulation. However, a long dark 
period then followed, in large 
part because it was unclear how 
chromatin could explain the 
specificity of gene regulation. This 
specificity problem was solved 
by the discovery that DNA- bound 
activators and repressors 
recruited nucleosome-remodeling 
complexes and histone acetylases 
to specific genomic locations, 
thereby creating localized 
perturbations in chromatin 
structure. This discovery, together 
with antibodies against specific 
histone modifications and 
advances in purifying protein 
complexes, has again rocketed 
chromatin to the forefront of the 
transcription field.
Nevertheless, while chromatin 
is clearly important for 
transcription, gene regulation 
is highly specific, and the 
DNA-binding proteins are the 
only entities with the requisite 
specificity to decode the genome. 
In fact, multiple DNA- binding 
proteins are required to achieve 
the specificity needed in 
large mammalian genomes. 
Furthermore, the pattern 
of histone modifications is 
generated by direct interactions 
of the relevant enzyme complexes 
with activators, repressors, and elongating RNA polymerase 
II. In my view, the stability of 
developmental states and gene 
regulatory patterns is determined 
primarily by the constellation 
of transcription factors in the 
particular cell type. The primary 
role of chromatin structure 
is to reinforce the regulatory 
decisions that are ultimately 
governed by transcription factors 
and the transcription process. 
Reinforcement occurs in large 
part by positive feedback loops, 
in which the true regulators 
function with ‘activating’ or 
‘repressing’ co- factors that both 
modify histones in specific ways 
and preferentially bind to those 
modified histones.
What do you think of the 
manuscript reviewing 
process? I think it is flawed 
at several levels. Anonymous 
reviews assume that reviewers 
are unbiased, objective and 
without personal or scientific 
conflicts of interest; this is 
not always true, especially in 
competitive situations, and 
there is no mechanism to 
detect such problems. Aside 
from the potential for abuse, 
anonymous reviews create an 
inequality between authors 
and reviewers that is unfair 
and scientifically unjustified. At 
many journals, particularly those 
run by commercial companies 
as opposed to scientific 
societies, disagreements 
between authors and reviewers 
are often adjudicated by 
editors with modest scientific 
accomplishments and experience. 
I favor a process in which editorial 
decisions are made by practising 
scientific experts, reviewers are 
identified by name, and the signed 
reviews and author responses 
published online along with the 
paper. Lastly, it is unfortunate 
that the biology community has 
permitted commercial companies 
to control most of the journals. 
Competition among journals and 
business-related decisions about 
scientific publishing has seriously 
distorted the literature, and it has 
created an artificial rating system 
that is used to judge decisions 
about funding and career 
advancement. How has the field of biology 
changed during your career? 
When I started, biology was a 
small and self-contained academic 
enterprise. Laboratories were 
small, individual students and 
fellows typically carried out all 
aspects of their own research 
project, and it was much less 
competitive to obtain faculty 
positions and research support. 
Now, biological research has an 
undeniable industrial flavor, even 
in academic institutions. Many 
projects are collaborative, often 
involving multiple laboratories 
with very different expertise. 
Individuals often perform highly 
specialized tasks, and there are 
management issues at all levels. 
Academic scientists now interact 
with a real biotechnology industry, 
complete with patents, lawyers, 
for-profit companies, and the 
potential to become personally 
wealthy. There is a trend away from 
small- scale, investigator-initiated, 
hypothesis-driven experiments to 
answer specific questions toward 
large-scale, high-throughput 
experiments designed to produce 
vast amounts of data. These large 
datasets are not only analyzed for 
their own sake, but they also serve 
as a general infrastructure for 
individual investigators. Personally, 
I prefer elucidating mechanisms 
rather than generating data, but 
both styles of research have great 
value, and we use them in my 
laboratory.
What is the future for gene 
regulation? I think that many, 
perhaps most, of the basic 
principles of gene regulation are 
already understood, although 
certainly there are interesting 
unanswered questions. Much 
less is known about the evolution 
of gene regulatory systems, 
both specific and general. In 
addition, elucidating the details 
of specific regulatory systems will 
become increasingly important in 
medicine, because for diagnosis 
and treatment of disease, the 
devil is in the details.
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